Abstract
The overexpression of anaplastic lymphoma kinase (ALK) had been found in many types of cancers, especially the non-small-cell lung cancers (NSCLCs). So the discovery of novel ALK inhibitor had attracted a great deal of interest in anticancer drugs research area. Presently, a combined study of 3D-quantitative structure-activity relationship (3DQSAR) and molecular docking was undertaken to explore the structural insights of 36 2-acyliminobenzimidazoles compounds influencing the ALK inhibitory activities. Both the ligand-based resultant comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) models exhibited good predictability (CoMFA with R2, 0.995; q2, 0.534; CoMSIA with R2, 0.993; q2, 0.519;). 3D contour maps and docking results suggested different groups on the core parts of the componds could enhance the biological activities. Finally, 10 derivatives as potential candidates of ALK inhibitors with excellent predicted activities were designed.
Keywords: 3D-QSAR, ALK inhibitor, CoMFA, CoMSIA, docking.
Letters in Drug Design & Discovery
Title:3D-QSAR and Docking Studies on 2-acyliminobenzimidazoles Derivatives as Potent ALK Inhibitors
Volume: 12 Issue: 3
Author(s): Qianqian Lva, Zhi Wang, Zhonghua Wanga*, Fanhong Wu*Liping Cheng
Affiliation:
- School of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai,China
- School of Chemical and Environmental Engineering, Shanghai Institute of Technology, Shanghai,China
Keywords: 3D-QSAR, ALK inhibitor, CoMFA, CoMSIA, docking.
Abstract: The overexpression of anaplastic lymphoma kinase (ALK) had been found in many types of cancers, especially the non-small-cell lung cancers (NSCLCs). So the discovery of novel ALK inhibitor had attracted a great deal of interest in anticancer drugs research area. Presently, a combined study of 3D-quantitative structure-activity relationship (3DQSAR) and molecular docking was undertaken to explore the structural insights of 36 2-acyliminobenzimidazoles compounds influencing the ALK inhibitory activities. Both the ligand-based resultant comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) models exhibited good predictability (CoMFA with R2, 0.995; q2, 0.534; CoMSIA with R2, 0.993; q2, 0.519;). 3D contour maps and docking results suggested different groups on the core parts of the componds could enhance the biological activities. Finally, 10 derivatives as potential candidates of ALK inhibitors with excellent predicted activities were designed.
Export Options
About this article
Cite this article as:
Lva Qianqian, Wang Zhi, Wanga Zhonghua*, Wu Fanhong*, Cheng Liping, 3D-QSAR and Docking Studies on 2-acyliminobenzimidazoles Derivatives as Potent ALK Inhibitors, Letters in Drug Design & Discovery 2015; 12 (3) . https://dx.doi.org/10.2174/1570180811666141010001624
DOI https://dx.doi.org/10.2174/1570180811666141010001624 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Drug Discovery Targeting Histone Methyltransferases: An Update
Current Medicinal Chemistry Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins
Recent Patents on Anti-Cancer Drug Discovery Clinical Trials with Oncolytic Adenovirus in China
Current Cancer Drug Targets Vitamin D: A Pleiotropic Hormone with Possible Psychotropic Activities
Current Medicinal Chemistry Targeting Angiogenesis in Head and Neck Cancer
Current Cancer Drug Targets Biomarker Assessment in Nutritional Modulation of Oxidative Stress-Induced Cancer Development by Lipid-Related Bioactive Molecules
Recent Patents on Anti-Cancer Drug Discovery Molecular Docking, Antioxidant, Anticancer and Antileishmanial Effects of Newly Synthesized Quinoline Derivatives
Anti-Cancer Agents in Medicinal Chemistry PEGylation: An Overview and Recent Advances Reported in the Patent Literature
Recent Patents on Chemical Engineering Decreased Parathyroid Hormone Levels Despite Persistent Hypocalcemia in Patients with Kidney Failure Recovering from Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Review of Novel Nanostructrued Devices, Nanofabrication Methods and Applications in Nanofluidics and Nanomedicine
Recent Patents on Nanotechnology A Structural Insight into Hydroxamic Acid Based Histone Deacetylase Inhibitors for the Presence of Anticancer Activity
Current Medicinal Chemistry The ModifiedGlasgow Prognostic Score and Survival in Colorectal Cancer: A Pooled Analysis of the Literature
Reviews on Recent Clinical Trials Prolonged Air Leak After Lung Resection
Current Respiratory Medicine Reviews Editorial [Hot Topic: Stem Cells and Tissue Regeneration (Executive Guest Editor: Roberta Di Pietro)]
Current Pharmaceutical Design Epigenetic Therapies and Potential Drugs for Treating Human Cancer
Current Drug Targets Prospects of Gene Therapy for Pulmonary Diseases: Progress and Limitations
Medicinal Chemistry Biomarker Metabolite Signatures Pave the Way for Electronic-nose Applications in Early Clinical Disease Diagnoses
Current Metabolomics Genome-wide Analysis of Myelodysplastic Syndromes
Current Pharmaceutical Design Pioglitazone Prevents Smoking Carcinogen-Induced Lung Tumor Development in Mice
Current Cancer Drug Targets The Need for Diagnostic Criteria in Systemic Vasculitis
Current Immunology Reviews (Discontinued)